基于水疱性口炎病毒(VSV)的溶瘤病毒研究进展 <sup>*</sup>

doi:10.13523/j.cb.2001014

中国生物工程杂志

2020, Vol. 40

Issue (6): 53-62 DOI: 10.13523/j.cb.2001014

综述

基于水疱性口炎病毒(VSV)的溶瘤病毒研究进展 ^*

张保惠^1,³,熊华龙^2,³,张天英^1,^3,^**(

),袁权^1,³

1 厦门大学公共卫生学院厦门 361102
2 厦门大学生命科学学院厦门 361102
3 国家传染病诊断试剂与疫苗工程技术研究中心厦门 361102

Research Progress on Vesicular Stomatitis Virus-based Oncolytic Virotherapy

ZHANG Bao-hui^1,³,XIONG Hua-long^2,³,ZHANG Tian-ying^1,^3,^**(

),YUAN Quan^1,³

1 School of Public Health, Xiamen University, Xiamen 361102, China
2 School of Life Sciences, Xiamen University, Xiamen 361102, China
3 National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Xiamen University, Xiamen 361102, China

全文: PDF(1033 KB) HTML

摘要：

溶瘤病毒利用肿瘤细胞抗病毒信号通路缺损或病毒受体过表达的特点,实现在其中选择性高复制进而杀伤肿瘤细胞,同时刺激机体产生特异性抗肿瘤免疫反应,是目前肿瘤治疗研究领域的热点。水疱性口炎病毒(vesicular stomatitis virus, VSV)能依赖肿瘤细胞干扰素信号通路的缺陷特异性靶向肿瘤细胞,具有复制高效、广泛组织嗜性、人群低致病性、基因组较小且易操纵等优势,是一种具有发展潜力的溶瘤病毒载体。对水疱性口炎病毒的病毒学特征以及目前基于VSV溶瘤病毒关于提高肿瘤选择性、延长半衰期、增强溶瘤效果的研究进展进行综述,为基于VSV溶瘤制剂的开发提供依据,为肿瘤治疗提供新的策略。

关键词： 溶瘤病毒; 水疱性口炎病毒; 肿瘤

Abstract:

Oncolytic virus utilizes the characteristics of tumor cells, such as deficiency of antiviral signaling pathway or overexpressing viral receptors, to preferentially infect, replicate in and kill tumor cells, which are emerging as important agents in cancer treatment. Due to the lack of interferon signaling pathways, tumor cells can be specifically targeted by vesicular stomatitis virus (VSV). VSV-based platform shows high prospects, as its efficient replication, broad tissue tropism, low pathogenicity to humans and its small and easy-to-manipulate genome. The virological characteristics of vesicular stomatitis virus and the current research progress of VSV-based oncolytic virus to improve tumor selectivity, extend half-life and increase oncolytic efficacy are discussed in this review.

Key words: Oncolytic viruses Vesicular stomatitis virus Tumor

收稿日期: 2020-01-03 出版日期: 2020-06-23

ZTFLH:

Q789

基金资助: * 国家自然科学基金青年科学基金(81702006)

通讯作者: 张天英 E-mail: tyzhang1003@163.com

	服务
	把本文推荐给朋友
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	张保惠
	熊华龙
	张天英
	袁权

引用本文:

张保惠,熊华龙,张天英,袁权. 基于水疱性口炎病毒(VSV)的溶瘤病毒研究进展 ^*[J]. 中国生物工程杂志, 2020, 40(6): 53-62.

ZHANG Bao-hui,XIONG Hua-long,ZHANG Tian-ying,YUAN Quan. Research Progress on Vesicular Stomatitis Virus-based Oncolytic Virotherapy. China Biotechnology, 2020, 40(6): 53-62.

链接本文:

https://manu60.magtech.com.cn/biotech/CN/10.13523/j.cb.2001014 或 https://manu60.magtech.com.cn/biotech/CN/Y2020/V40/I6/53

图1 VSV的结构及其诱导的抗肿瘤机制

表1 代表性的重组VSV溶瘤病毒

[1]	Choi A H, O’Leary M P, Fong Y , et al. From benchtop to bedside: a review of oncolytic virotherapy. Biomedicines, 2016,4(3):18.
[2]	Garber K . China approves world’s first oncolytic virus therapy for cancer treatment. J Natl Cancer Inst, 2006,98(5):298-300. doi: 10.1093/jnci/djj111 pmid: 16507823
[3]	Andtbacka R H, Kaufman H L, Collichio F , et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol, 2015,33(25):2780-2788.
[4]	Drolet B S, Stuart M A, Derner J D . Infection of melanoplus sanguinipes grasshoppers following ingestion of rangeland plant species harboring vesicular stomatitis virus. Appl Environ Microbiol, 2009,75(10):3029-3033.
[5]	Banerjee A K . The transcription complex of vesicular stomatitis virus. Cell, 1987,48(3):363-364. pmid: 3026646
[6]	Johannsdottir H K, Mancini R, Kartenbeck J , et al. Host cell factors and functions involved in vesicular stomatitis virus entry. J Virol, 2009,83(1):440-453.
[7]	Shi Z, Cai Z, Sanchez A , et al. A novel toll-like receptor that recognizes vesicular stomatitis virus. J Biol Chem, 2011,286(6):4517-4524.
[8]	Hornung V, Ellegast J, Kim S , et al. 5'-triphosphate rna is the ligand for rig-i. Science, 2006,314(5801):994-997. doi: 10.1126/science.1132505 pmid: 17038590
[9]	Weidner J M, Jiang D, Pan X B , et al. Interferon-induced cell membrane proteins, ifitm3 and tetherin, inhibit vesicular stomatitis virus infection via distinct mechanisms. J Virol, 2010,84(24):12646-12657. pmid: 20943977
[10]	Sarojini S, Theofanis T, Reiss C S . Interferon-induced tetherin restricts vesicular stomatitis virus release in neurons. DNA Cell Biol, 2011,30(12):965-974.
[11]	Wang B X, Rahbar R, Fish E N . Interferon: current status and future prospects in cancer therapy. J Interferon Cytokine Res, 2011,31(7):545-552. doi: 10.1089/jir.2010.0158 pmid: 21323567
[12]	Ahmed M, Lyles D S . Effect of vesicular stomatitis virus matrix protein on transcription directed by host rna polymerases i, ii, and iii. J Virol, 1998,72(10):8413-8419.
[13]	Black B L, Lyles D S . Vesicular stomatitis virus matrix protein inhibits host cell-directed transcription of target genes in vivo. J Virol, 1992,66(7):4058-4064. pmid: 1318397
[14]	Enninga J, Levy D E, Blobel G , et al. Role of nucleoporin induction in releasing an mrna nuclear export block. Science, 2002,295(5559):1523-1525.
[15]	Faria P A, Chakraborty P, Levay A , et al. Vsv disrupts the rae1/mrnp41 mrna nuclear export pathway. Mol Cell, 2005,17(1):93-102.
[16]	Rajani K R, Pettit Kneller E L, McKenzie M O , et al. Complexes of vesicular stomatitis virus matrix protein with host rae1 and nup98 involved in inhibition of host transcription. PLoS Pathog, 2012,8(9):e1002929.
[17]	Altomonte J, Wu L, Meseck M , et al. Enhanced oncolytic potency of vesicular stomatitis virus through vector-mediated inhibition of nk and nkt cells. Cancer Gene Ther, 2009,16(3):266-278. pmid: 18846115
[18]	Bommareddy P K, Shettigar M, Kaufman H L . Integrating oncolytic viruses in combination cancer immunotherapy. Nat Rev Immunol, 2018,18(8):498-513. doi: 10.1038/s41577-018-0014-6 pmid: 29743717
[19]	Stojdl D F, Lichty B, Knowles S , et al. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med, 2000,6(7):821-825.
[20]	Melzer M K, Lopez-Martinez A, Altomonte J . Oncolytic vesicular stomatitis virus as a viro-immunotherapy: defeating cancer with a “hammer” and “anvil”. Biomedicines, 2017,5(1):8. doi: 10.3390/biomedicines5010008
[21]	Connor J H, Naczki C, Koumenis C , et al. Replication and cytopathic effect of oncolytic vesicular stomatitis virus in hypoxic tumor cells in vitro and in vivo. J Virol, 2004,78(17):8960-8970. doi: 10.1128/JVI.78.17.8960-8970.2004
[22]	Dal Canto M C, Rabinowitz S G, Johnson T C . Status spongiousus resulting from intracerebral infection of mice with temperature-sensitive mutants of vesicular stomatitis virus. Br J Exp Pathol, 1976,57(3):321-330. pmid: 182197
[23]	Plakhov I V, Arlund E E, Aoki C , et al. The earliest events in vesicular stomatitis virus infection of the murine olfactory neuroepithelium and entry of the central nervous system. Virology, 1995,209(1):257-262. pmid: 7747478
[24]	Shinozaki K, Ebert O, Suriawinata A , et al. Prophylactic alpha interferon treatment increases the therapeutic index of oncolytic vesicular stomatitis virus virotherapy for advanced hepatocellular carcinoma in immune-competent rats. J Virol, 2005,79(21):13705-13713. doi: 10.1128/JVI.79.21.13705-13713.2005 pmid: 16227290
[25]	Schellekens H, miers-de Vreede S E, de Reus A , et al. Antiviral activity of interferon in rats and the effect of immune suppression. J Gen Virol, 1984,65(Pt 2):391-396.
[26]	Johnson J E, Nasar F, Coleman J W , et al. Neurovirulence properties of recombinant vesicular stomatitis virus vectors in non-human primates. Virology, 2007,360(1):36-49.
[27]	Gray Z, Tabarraei A, Moradi A , et al. M51r and delta-m51 matrix protein of the vesicular stomatitis virus induce apoptosis in colorectal cancer cells. Mol Biol Rep, 2019,46(3):3371-3379. doi: 10.1007/s11033-019-04799-3 pmid: 31006094
[28]	Day G L, Bryan M L, Northrup S A , et al. Immune effects of m51r vesicular stomatitis virus treatment of carcinomatosis from colon cancer. J Surg Res, 2020,245:127-135. doi: 10.1016/j.jss.2019.07.032 pmid: 31415934
[29]	Ammayappan A, Nace R, Peng K W , et al. Neuroattenuation of vesicular stomatitis virus through picornaviral internal ribosome entry sites.[J] Virol. 2013,87(6):3217-3228.
[30]	Janelle V, Brassard F, Lapierre P , et al. Mutations in the glycoprotein of vesicular stomatitis virus affect cytopathogenicity: potential for oncolytic virotherapy. J Virol, 2011,85(13):6513-6520.
[31]	Roberts A, Kretzschmar E, Perkins A S , et al. Vaccination with a recombinant vesicular stomatitis virus expressing an influenza virus hemagglutinin provides complete protection from influenza virus challenge. J Virol, 1998,72(6):4704-4711. pmid: 9573234
[32]	Duntsch C D, Zhou Q, Jayakar H R , et al. Recombinant vesicular stomatitis virus vectors as oncolytic agents in the treatment of high-grade gliomas in an organotypic brain tissue slice-glioma coculture model. J Neurosurg, 2004,100(6):1049-1059.
[33]	Ammayappan A, Peng K W, Russell S J . Characteristics of oncolytic vesicular stomatitis virus displaying tumor-targeting ligands. J Virol, 2013,87(24):13543-13555. pmid: 24089573
[34]	Ayala-Breton C, Russell L O, Russell S J , et al. Faster replication and higher expression levels of viral glycoproteins give the vesicular stomatitis virus/measles virus hybrid vsv-fh a growth advantage over measles virus. J Virol, 2014,88(15):8332-8339.
[35]	Van den Pol A N, Mao G, Chattopadhyay A , et al. Chikungunya, influenza, nipah, and semliki forest chimeric viruses with vesicular stomatitis virus: actions in the brain. J Virol, 2017,91(6):e02154-02116. pmid: 28077641
[36]	Wollmann G, Drokhlyansky E, Davis J N , et al. Lassa-vesicular stomatitis chimeric virus safely destroys brain tumors. J Virol, 2015,89(13):6711-6724. doi: 10.1128/JVI.00709-15 pmid: 25878115
[37]	Muik A, Stubbert L J, Jahedi R Z , et al. Re-engineering vesicular stomatitis virus to abrogate neurotoxicity, circumvent humoral immunity, and enhance oncolytic potency. Cancer Res, 2014,74(13):3567-3578.
[38]	Iverson L E, Rose J K . Localized attenuation and discontinuous synthesis during vesicular stomatitis virus transcription. Cell, 1981,23(2):477-484. pmid: 6258804
[39]	Flanagan E B, Schoeb T R, Wertz G W . Vesicular stomatitis viruses with rearranged genomes have altered invasiveness and neuropathogenesis in mice. J Virol, 2003,77(10):5740-5748. pmid: 12719567
[40]	Van den Pol A N, Davis J N . Highly attenuated recombinant vesicular stomatitis virus vsv-12'gfp displays immunogenic and oncolytic activity. J Virol, 2013,87(2):1019-1034. doi: 10.1128/JVI.01106-12 pmid: 23135719
[41]	Muik A, Dold C, Geiss Y , et al. Semireplication-competent vesicular stomatitis virus as a novel platform for oncolytic virotherapy. J Mol Med (Berl), 2012,90(8):959-970.
[42]	Kelly E J, Nace R, Barber G N , et al. Attenuation of vesicular stomatitis virus encephalitis through microrna targeting. J Virol, 2010,84(3):1550-1562. pmid: 19906911
[43]	Edge R E, Falls T J, Brown C W , et al. A let-7 microrna-sensitive vesicular stomatitis virus demonstrates tumor-specific replication. Mol Ther, 2008,16(8):1437-1443. doi: 10.1038/mt.2008.130 pmid: 18560417
[44]	Power A T, Wang J, Falls T J , et al. Carrier cell-based delivery of an oncolytic virus circumvents antiviral immunity. Mol Ther, 2007,15(1):123-130. pmid: 17164783
[45]	Muharemagic D, Zamay A, Ghobadloo S M , et al. Aptamer-facilitated protection of oncolytic virus from neutralizing antibodies. Mol Ther Nucleic Acids, 2014,3:e167. pmid: 24892725
[46]	Tesfay M Z, Kirk A C, Hadac E M , et al. Pegylation of vesicular stomatitis virus extends virus persistence in blood circulation of passively immunized mice. J Virol, 2013,87(7):3752-3759. doi: 10.1128/JVI.02832-12 pmid: 23325695
[47]	Altomonte J, Wu L, Chen L , et al. Exponential enhancement of oncolytic vesicular stomatitis virus potency by vector-mediated suppression of inflammatory responses in vivo. Mol Ther, 2008,16(1):146-153.
[48]	Wu L, Huang T G, Meseck M , et al. Rvsv(m delta 51)-m3 is an effective and safe oncolytic virus for cancer therapy. Hum Gene Ther, 2008,19(6):635-647.
[49]	Kannan K, Amariglio N, Rechavi G , et al. DNA microarrays identification of primary and secondary target genes regulated by p53. Oncogene, 2001,20(18):2225-2234.
[50]	Heiber J F, Barber G N . Vesicular stomatitis virus expressing tumor suppressor p53 is a highly attenuated, potent oncolytic agent. J Virol, 2011,85(20):10440-10450.
[51]	Hastie E, Cataldi M, Steuerwald N , et al. An unexpected inhibition of antiviral signaling by virus-encoded tumor suppressor p53 in pancreatic cancer cells. Virology, 2015,483:126-140. doi: 10.1016/j.virol.2015.04.017 pmid: 25965802
[52]	Yamamoto S, Suzuki S, Hoshino A , et al. Herpes simplex virus thymidine kinase/ganciclovir-mediated killing of tumor cell induces tumor-specific cytotoxic t cells in mice. Cancer Gene Ther. 1997,4(2):91-96.
[53]	Fernandez M, Porosnicu M, Markovic D , et al. Genetically engineered vesicular stomatitis virus in gene therapy: application for treatment of malignant disease. J Virol, 2002,76(2):895-904. doi: 10.1128/jvi.76.2.895-904.2002 pmid: 11752178
[54]	Kanai F, Kawakami T, Hamada H , et al. Adenovirus-mediated transduction of Escherichia coli uracil phosphoribosyltransferase gene sensitizes cancer cells to low concentrations of 5-fluorouracil. Cancer Res, 1998,58(9):1946-1951. pmid: 9581837
[55]	Adachi Y, Tamiya T, Ichikawa T , et al. Experimental gene therapy for brain tumors using adenovirus-mediated transfer of cytosine deaminase gene and uracil phosphoribosyltransferase gene with 5-fluorocytosine. Hum Gene Ther, 2000,11(1):77-89. doi: 10.1089/10430340050016175 pmid: 10646641
[56]	Erbs P, Regulier E, Kintz J , et al. In vivo cancer gene therapy by adenovirus-mediated transfer of a bifunctional yeast cytosine deaminase/uracil phosphoribosyltransferase fusion gene. Cancer Res, 2000,60(14):3813-3822. pmid: 10919655
[57]	Chung-Faye G A, Chen M J, Green N K , et al. In vivo gene therapy for colon cancer using adenovirus-mediated, transfer of the fusion gene cytosine deaminase and uracil phosphoribosyltransferase. Gene Ther, 2001,8(20):1547-1554. doi: 10.1038/sj.gt.3301557 pmid: 11704815
[58]	Leveille S, Samuel S, Goulet M L , et al. Enhancing vsv oncolytic activity with an improved cytosine deaminase suicide gene strategy. Cancer Gene Ther, 2011,18(6):435-443. doi: 10.1038/cgt.2011.14 pmid: 21394109
[59]	Porosnicu M, Mian A, Barber G N . The oncolytic effect of recombinant vesicular stomatitis virus is enhanced by expression of the fusion cytosine deaminase/uracil phosphoribosyltransferase suicide gene. Cancer Res, 2003,63(23):8366-8376. pmid: 14678998
[60]	Ebert O, Shinozaki K, Kournioti C , et al. Syncytia induction enhances the oncolytic potential of vesicular stomatitis virus in virotherapy for cancer. Cancer Res, 2004,64(9):3265-3270. doi: 10.1158/0008-5472.can-03-3753 pmid: 15126368
[61]	Le Boeuf F, Gebremeskel S, McMullen N , et al. Reovirus fast protein enhances vesicular stomatitis virus oncolytic virotherapy in primary and metastatic tumor models. Mol Ther Oncolytics, 2017,6:80-89.
[62]	Samuel S, Beljanski V, Van Grevenynghe J , et al. Bcl-2 inhibitors sensitize therapy-resistant chronic lymphocytic leukemia cells to vsv oncolysis. Mol Ther, 2013,21(7):1413-1423. doi: 10.1038/mt.2013.91 pmid: 23689597
[63]	Dobson C C, Naing T, Beug S T , et al. Oncolytic virus synergizes with smac mimetic compounds to induce rhabdomyosarcoma cell death in a syngeneic murine model. Oncotarget. 2017,8(2):3495-3508. doi: 10.18632/oncotarget.13849 pmid: 27966453
[64]	Altomonte J, Braren R, Schulz S , et al. Synergistic antitumor effects of transarterial viroembolization for multifocal hepatocellular carcinoma in rats. Hepatology, 2008,48(6):1864-1873. doi: 10.1002/hep.22546 pmid: 19003878
[65]	Goel A, Carlson S K, Classic K L , et al. Radioiodide imaging and radiovirotherapy of multiple myeloma using vsv(delta51)-nis, an attenuated vesicular stomatitis virus encoding the sodium iodide symporter gene. Blood, 2007,110(7):2342-2350. doi: 10.1182/blood-2007-01-065573 pmid: 17515401
[66]	Shin E J, Wanna G B, Choi B , et al. Interleukin-12 expression enhances vesicular stomatitis virus oncolytic therapy in murine squamous cell carcinoma. Laryngoscope, 2007,117(2):210-214. doi: 10.1097/01.mlg.0000246194.66295.d8 pmid: 17204993
[67]	Stephenson K B, Barra N G, Davies E , et al. Expressing human interleukin-15 from oncolytic vesicular stomatitis virus improves survival in a murine metastatic colon adenocarcinoma model through the enhancement of anti-tumor immunity. Cancer Gene Ther, 2012,19(4):238-246. doi: 10.1038/cgt.2011.81
[68]	Miller J M, Bidula S M, Jensen T M , et al. Vesicular stomatitis virus modified with single chain il-23 exhibits oncolytic activity against tumor cells in vitro and in vivo. Int J Interferon Cytokine Mediat Res, 2010,2010(2):63-72. doi: 10.2147/ijicmr.s9528 pmid: 20556219
[69]	Wongthida P, Diaz R M, Galivo F , et al. Type iii ifn interleukin-28 mediates the antitumor efficacy of oncolytic virus vsv in immune-competent mouse models of cancer. Cancer Res, 2010,70(11):4539-4549. doi: 10.1158/0008-5472.CAN-09-4658 pmid: 20484025
[70]	Leveille S, Goulet M L, Lichty B D , et al. Vesicular stomatitis virus oncolytic treatment interferes with tumor-associated dendritic cell functions and abrogates tumor antigen presentation. J Virol, 2011,85(23):12160-12169. doi: 10.1128/JVI.05703-11
[71]	Galivo F, Diaz R M, Thanarajasingam U , et al. Interference of cd40l-mediated tumor immunotherapy by oncolytic vesicular stomatitis virus. Hum Gene Ther, 2010,21(4):439-450. doi: 10.1089/hum.2009.143 pmid: 19922169
[72]	Obuchi M, Fernandez M, Barber G N . Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity. J Virol, 2003,77(16):8843-8856. doi: 10.1128/jvi.77.16.8843-8856.2003 pmid: 12885903
[73]	Pulido J, Kottke T, Thompson J , et al. Using virally expressed melanoma cdna libraries to identify tumor-associated antigens that cure melanoma. Nat Biotechnol, 2012,30(4):337-343. doi: 10.1038/nbt.2157 pmid: 22426030
[74]	Cockle J V, Rajani K, Zaidi S , et al. Combination viroimmunotherapy with checkpoint inhibition to treat glioma, based on location-specific tumor profiling. Neuro Oncol, 2016,18(4):518-527. doi: 10.1093/neuonc/nov173 pmid: 26409567
[75]	Blanchard M, Shim K G, Grams M P , et al. Definitive management of oligometastatic melanoma in a murine model using combined ablative radiation therapy and viral immunotherapy. Int J Radiat Oncol Biol Phys, 2015,93(3):577-587. doi: 10.1016/j.ijrobp.2015.07.2274 pmid: 26461000
[76]	Rommelfanger D M, Wongthida P, Diaz R M , et al. Systemic combination virotherapy for melanoma with tumor antigen-expressing vesicular stomatitis virus and adoptive t-cell transfer. Cancer Res, 2012,72(18):4753-4764. doi: 10.1158/0008-5472.CAN-12-0600 pmid: 22836753
[77]	Rommelfanger D M, Compte M, Diaz R M , et al. The efficacy versus toxicity profile of combination virotherapy and tlr immunotherapy highlights the danger of administering tlr agonists to oncolytic virus-treated mice. Mol Ther, 2013,21(2):348-357. doi: 10.1038/mt.2012.204
[78]	Shen W, Patnaik M M, Ruiz A , et al. Immunovirotherapy with vesicular stomatitis virus and pd-l1 blockade enhances therapeutic outcome in murine acute myeloid leukemia. Blood, 2016,127(11):1449-1458. doi: 10.1182/blood-2015-06-652503 pmid: 26712908
[79]	Durham N M, Mulgrew K, McGlinchey K , et al. Oncolytic vsv primes differential responses to immuno-oncology therapy. Mol Ther, 2017,25(8):1917-1932. doi: 10.1016/j.ymthe.2017.05.006 pmid: 28578991
[80]	Wu C, Wu M, Liang M , et al. A novel oncolytic virus engineered with pd-l1 scfv effectively inhibits tumor growth in a mouse model. Cell Mol Immunol, 2019,16(9):780-782. doi: 10.1038/s41423-019-0264-7 pmid: 31363172
[81]	Publicover J, Ramsburg E, Robek M , et al. Rapid pathogenesis induced by a vesicular stomatitis virus matrix protein mutant: viral pathogenesis is linked to induction of tumor necrosis factor alpha. J Virol, 2006,80(14):7028-7036. doi: 10.1128/JVI.00478-06 pmid: 16809308
[82]	Jenks N, Myers R, Greiner S M , et al. Safety studies on intrahepatic or intratumoral injection of oncolytic vesicular stomatitis virus expressing interferon-beta in rodents and nonhuman primates. Hum Gene Ther, 2010,21(4):451-462. doi: 10.1089/hum.2009.111 pmid: 19911974
[83]	Vyriad I . Administration of vsv-ifnβ-nis monotherapy and in combination with avelumab in patients with refractory solid tumors. [2020-01-02]. https://clinicaltrials.gov/ct2/show/NCT02923466?term=VSV&cond=CANCER&draw=2&rank=1.
[84]	Vyriad I . Combination therapy with intravenous vsv-ifnβ-nis and pembrolizumab in refractory nsclc and hnscc. [2020-01-02]. https://clinicaltrials.gov/ct2/show/NCT03647163?term=VSV&cond=CANCER&draw=2&rank=2.
[85]	Clinic M . Vsv-hifnbeta-nis in treating patients with stage iv or recurrent endometrial cancer. [2020-01-02]. https://clinicaltrials.gov/ct2/show/NCT03120624?term=VSV&cond=CANCER&draw=2&rank=3.
[86]	Clinic M . Vsv-hifnbeta-nis in treating patients with relapsed or refractory multiple myeloma, acute myeloid leukemia, or t-cell lymphoma. [2020-01-02]. https://clinicaltrials.gov/ct2/show/NCT03017820?term=VSV&cond=CANCER&draw=2&rank=6.
[87]	Clinic M . Viral therapy in treating patient with refractory liver cancer or advanced solid tumors. [2020-01-02]. https://clinicaltrials.gov/ct2/show/NCT01628640?term=VSV&cond=CANCER&draw=2&rank=5.
[88]	Clinic M . Modified virus vsv-ifnbetatyrp1 in treating patients with stage iii-iv melanoma. [2020-01-02]. https://clinicaltrials.gov/ct2/show/NCT03865212?term=VSV&cond=CANCER&draw=2&rank=7.

[1]	赵梦泽,李凤智,王鹏银,李剑,徐寒梅. PD-L1和VEGF双靶点联合阻断治疗的研究进展[J]. 中国生物工程杂志, 2021, 41(9): 71-77.
[2]	吕慧中,赵晨辰,朱链,许娜. 外泌体靶向递药在肿瘤治疗中的进展[J]. 中国生物工程杂志, 2021, 41(5): 79-86.
[3]	原博,王杰文,康广博,黄鹤. 双特异性纳米抗体的研究进展及其应用 ^*[J]. 中国生物工程杂志, 2021, 41(2/3): 78-88.
[4]	邓蕊,曾佳利,卢雪梅. 基于Musca domestica cecropin的抗肿瘤小分子衍生肽筛选及构效关系解析^*[J]. 中国生物工程杂志, 2021, 41(11): 14-22.
[5]	蔺士新,刘东晨,雷云,熊盛,谢秋玲. TNF-α纳米抗体的筛选、表达及特异性检测 ^*[J]. 中国生物工程杂志, 2020, 40(7): 15-21.
[6]	杨威,宋方祥,王帅,张黎,王红霞,李焱. 药物输送系统中Janus纳米粒子的制备及应用 ^*[J]. 中国生物工程杂志, 2020, 40(7): 70-81.
[7]	童梅,程永庆,刘金毅,徐晨. 促进大肠杆菌周质空间小分子抗体表达的菌种构建方法^*[J]. 中国生物工程杂志, 2020, 40(5): 48-56.
[8]	戴奇男,张景红. 肿瘤多药耐药与自噬、DNA修复和肿瘤干细胞相关的分子机制研究进展 ^*[J]. 中国生物工程杂志, 2020, 40(4): 69-77.
[9]	钱颖,钱晨,白晓庆,王晶晶. 免疫佐剂在肿瘤免疫疗法中的应用进展 ^*[J]. 中国生物工程杂志, 2020, 40(3): 96-103.
[10]	肖雪筠,唐奇,新华·那比. 靶向肿瘤微环境的CAR-T治疗研究^*[J]. 中国生物工程杂志, 2020, 40(12): 67-74.
[11]	何询,张鹏,张俊祥. 类器官的构建与应用进展[J]. 中国生物工程杂志, 2020, 40(12): 82-87.
[12]	朱永朝,陶金,任萌萌,熊燃,何亚琴,周瑜,卢震辉,杜勇,杨芝红. 自噬抑制肿瘤坏死因子α诱导人胎盘胎儿来源间充质干细胞发生凋亡 ^*[J]. 中国生物工程杂志, 2019, 39(9): 62-67.
[13]	彭贤贵,杨武晨,李佳,苟阳,王平,刘思恒,张云,李艺,张曦. 细胞形态相关技术在血液系统肿瘤中的应用 ^*[J]. 中国生物工程杂志, 2019, 39(9): 84-90.
[14]	刘艳,戴鹏,朱运峰. 外泌体作为肿瘤标志物的研究进展 ^*[J]. 中国生物工程杂志, 2019, 39(8): 74-79.
[15]	张裕丰,谢梦佳,周舒蕾,徐玲玲,赵铁军. 细胞穿膜肽在肿瘤靶向治疗及疾病诊断中的应用 ^*[J]. 中国生物工程杂志, 2019, 39(6): 48-54.

Viewed

Full text

Abstract

Cited

Shared

Discussed